The near-term Hims & Hers growth outlook looks abysmal on the back of the weight loss drug news that now comes with legal and regulatory overhangs. I would argue that we have big downside to estimates from the sloths that are the sell side analysts. Take a look at where we stand into this afternoon’s results:
Substack is the home for great culture